FDA approves Watson's generic BONIVA ANDA to treat osteoporosis in women

NewsGuard 100/100 Score
Mar 21 2012

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA® tablets.

Watson intends to begin shipping the product in the second quarter. BONIVA® 150mg tablets had total U.S. sales of approximately $510 million for the twelve months ending January 31, 2012, according to IMS Health.  Ibandronate tablets are indicated to prevent and treat osteoporosis in women who have undergone menopause.  Roche has sued Watson for patent infringement in connection with Watson's ANDA for Ibandronate 150mg tablets.  That lawsuit remains pending.

SOURCE Watson Pharmaceuticals, Inc.

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Higher doses of topical corticosteroids linked to increased risks of osteoporosis and bone fractures
Prevention of post-menopausal osteoporosis in rats by sesame oil
The effects of vitamin K on bone health
Tea consumption increases bone density and reduces the risk of osteoporosis
Adolescent sports participation associated with higher bone mineral density in old age
Study links heavy metals to depleted ovarian reserves
Sesame oil supplementation: a potential breakthrough in postmenopausal osteoporosis prevention?
New study reveals optimal drug sequencing for postmenopausal osteoporosis treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
How residential green spaces impact bone health and osteoporosis risk